Home β€Ί Stock analysis β€Ί BBLGW

Bone Biologics (BBLGW) Stock Analysis & Price (Updated Oct 12, 2026, 4:00 PM ET)

Updated Oct 12, 2026, 4:00 PM ET

What changed since yesterday

BBLGW ends flat (+0.0%) to $7.70. Closed at $7.70, +0.00% vs the prior close of $7.70. Day range $7.70–$7.70, opened at $7.70.

Last close$7.70+0.00%
Day range7.70–7.70
Open7.70
Volume0
52-week range3.50–35.95
Avg volume (20d)1.70K

BBLGW daily analysis β€” what happened

A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.

Oct 12, 2026 β€” BBLGW ends flat (+0.0%) to $7.70
Oct 9, 2026 β€” BBLGW jumps 17.8% to $7.70 on 20.1x normal volume
Oct 8, 2026 β€” BBLGW ends flat (+0.0%) to $6.53, 3 down days in a row
Oct 7, 2026 β€” BBLGW ends flat (+0.0%) to $6.53
Oct 6, 2026 β€” BBLGW slides 15.1% to $6.53
Oct 5, 2026 β€” BBLGW jumps 39.2% to $7.70, a 1-month high on 10.4x normal volume
Oct 2, 2026 β€” BBLGW jumps 28.6% to $5.53 on 12.7x normal volume
Oct 1, 2026 β€” BBLGW jumps 13.2% to $4.30
Sep 30, 2026 β€” BBLGW slides 6.4% to $3.80, a 1-month low on 1.9x normal volume
Sep 29, 2026 β€” BBLGW ends flat (+0.0%) to $4.06, 10 down days in a row

BBLGW latest news & SEC filings

Every SEC filing by or about BBLGW in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.

Oct 13, 2026 Β· Form 25-NSE β€” Notice that a security is being removed from exchange listing

Notice that a security is being removed from exchange listing

Source: SEC EDGAR filing 0001354457-26-000978

Sep 30, 2026 Β· Form 4 β€” Insider trade

Insider trade report (Form 4) β€” a director, officer or 10%+ owner changed their holdings

Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).

Source: SEC EDGAR filing 0001493152-26-045149

Sep 30, 2026 Β· Form 4 β€” Insider trade

Insider trade report (Form 4) β€” a director, officer or 10%+ owner changed their holdings

Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).

Source: SEC EDGAR filing 0001493152-26-045147

Sep 30, 2026 Β· Form 4 β€” Insider trade

Insider trade report (Form 4) β€” a director, officer or 10%+ owner changed their holdings

Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).

Source: SEC EDGAR filing 0001493152-26-045140

Sep 30, 2026 Β· Form 4 β€” Insider trade

Insider trade report (Form 4) β€” a director, officer or 10%+ owner changed their holdings

Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).

Source: SEC EDGAR filing 0001493152-26-045135

Sep 29, 2026 Β· Form 8-K β€” Major event / current report

Current report β€” a filing companies must make within 4 business days of a major event

Source: SEC EDGAR filing 0001493152-26-044889

Sep 16, 2026 Β· Form 8-K β€” Major event / current report

Current report β€” a filing companies must make within 4 business days of a major event

Source: SEC EDGAR filing 0001493152-26-042940

Aug 28, 2026 Β· Form DEF 14A β€” Proxy statement

Proxy statement β€” agenda for the shareholder meeting (board elections, executive pay, votes)

Source: SEC EDGAR filing 0001493152-26-040640

Aug 18, 2026 Β· Form PRE 14A β€” Preliminary proxy statement

Preliminary proxy statement

Source: SEC EDGAR filing 0001493152-26-039034

Aug 14, 2026 Β· Form 10-Q β€” Quarterly report

Quarterly report (unaudited financial statements for the quarter)

Quarter ended Jun 30, 2026:

Source: SEC EDGAR filing 0001493152-26-038482

Jul 24, 2026 Β· Form EFFECT β€” EFFECT filing

EFFECT filing

Source: SEC EDGAR filing 9999999995-26-002449

Jul 24, 2026 Β· Form 424B3 β€” Prospectus / supplement for an offering or resale

Prospectus / supplement for an offering or resale

An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.

Source: SEC EDGAR filing 0001493152-26-034605

Jul 23, 2026 Β· Form 8-K β€” Major event / current report

Current report β€” a filing companies must make within 4 business days of a major event

Source: SEC EDGAR filing 0001493152-26-034334

Jul 20, 2026 Β· Form DEFA14A β€” Additional proxy materials

Additional proxy materials

Source: SEC EDGAR filing 0001493152-26-033938

Jul 17, 2026 Β· Form S-3 β€” Shelf registration (S-3)

Shelf registration (S-3) β€” lets the company sell securities over time

An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.

Source: SEC EDGAR filing 0001493152-26-033789

Things to know before you trade BBLGW

BBLGW market data (last 20 sessions)

DateOpenHighLowCloseVolume
Oct 12, 20267.707.707.707.700
Oct 9, 20265.3912.005.397.7013.40K
Oct 8, 20266.536.536.536.530
Oct 7, 20266.536.536.536.530
Oct 6, 20266.536.536.536.531.00K
Oct 5, 20265.997.704.407.705.60K
Oct 2, 20265.997.995.535.535.50K
Oct 1, 20264.304.304.304.30500
Sep 30, 20264.284.283.803.801.20K
Sep 29, 20264.064.064.064.060
Sep 28, 20264.064.064.064.060
Sep 25, 20264.064.064.064.060
Sep 24, 20264.064.064.064.060
Sep 23, 20264.064.064.064.060
Sep 22, 20264.064.064.064.060
Sep 21, 20264.064.064.064.060
Sep 18, 20264.054.103.924.06600
Sep 17, 20265.705.704.224.301.00K
Sep 16, 20265.886.005.005.002.20K
Sep 15, 20267.307.486.106.103.00K

About Bone Biologics

Bone Biologics (BBLGW) is listed on the Nasdaq and classified by the SEC under β€œOrthopedic, Prosthetic & Surgical Appliances & Supplies”. Its business address is in BURLINGTON, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1419554.

BBLGW board of directors & executives

From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).

Directors

NameRoleLatest filing
Siddhesh Rajendra AngleDirectorSep 30, 2026
Robert E. GagnonDirectorSep 30, 2026
Phillip Terry Ii MeikleDirectorSep 30, 2026
Bruce StroeverDirectorSep 30, 2026

Executive officers

NameTitleLatest filing
Jeff FrelickChief Executive OfficerJan 21, 2026
Deina H WalshChief Financial OfficerJan 21, 2026

Recent insider buys & sales

DateInsiderTypeSharesPrice
No open-market insider buys or sales reported in the last 12 months.

BBLGW financials (annual, from XBRL filings)

Fiscal year endRevenueNet incomeDiluted EPSOperating cash flow
Dec 31, 2025β€”$-3.11M-2.65$-2.69M
Dec 31, 2024β€”$-4.11M-28.96$-4.12M
Dec 31, 2023β€”$-8.95M-34.01$-9.56M
Dec 31, 2022β€”$-1.48M-31.15$-3.57M
Dec 31, 2021β€”$-1.61Mβ€”$-1.23M

Latest balance sheet: total assets $4.44M, total liabilities $512.02K, cash $6.19M (as of Jun 30, 2026).

BBLGW earnings / results-day log

DateFilingClose that day
No 8-K earnings releases in recent filings.

Related stocks Β· Orthopedic, Prosthetic & Surgical Appliances & Supplies

Intuitive Surgical (ISRG)Edwards Lifesciences (EW)Zimmer Biomet (ZBH)Align Technology (ALGN)Steris (STE)MSA Safety (MSA)Smith & Nephew (SNN)Enovis (ENOV)Establishment Labs (ESTA)Cadre (CDRE)

Popular today

Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)

More on BBLGW

Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 12, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.